Synthetic Genomics and Ceva Enter Agreement to Develop, Commercialize Next-Generation Vaccines for Animal Health

SAN DIEGO – October 31, 2017 – Synthetic Genomics, Inc. announced today that the company has entered into a collaboration with Ceva Santé Animale to utilize Synthetic Genomics’ next-generation synthetic RNA replicon platform to develop vaccines for livestock. The technology opens the door to more effective vaccines and therapeutics.

Synthetic Genomics’ RNA replicons are programed to deliver genetic instructions to a body’s own cells to unleash a powerful immune response against a specific disease. These RNA replicons carry the genetic code for a self-replication engine as well as antigens that signal for an immune response. The self-amplifying RNA-based vaccine triggers rapid and immediate antigen expression within host cells, which induces strong T cell and B cell responses. These fully synthetic vaccines have lower dose requirements and simplified manufacturing compared to traditional vaccine approaches.

“We have made tremendous progress to date in programming RNA to develop next-generation vaccines that are multigenic, tunable and, most importantly, scalable for commercially competitive markets, such as animal health,” said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. “This partnership with Ceva, a leader in animal health, highlights the promise in deploying our synthetic biology capabilities to build RNA systems capable of improving global health in a variety of ways.”

Financial terms of the agreement are not disclosed at this time.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in energy, health care and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at

About Ceva
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne , France

Synthetic Genomics
Corporate Communications and Media
Jason Spark, Canale Communications